Your browser is no longer supported. Please, upgrade your browser.
Cortexyme, Inc.
Index- P/E- EPS (ttm)-2.94 Insider Own1.40% Shs Outstand29.59M Perf Week6.68%
Market Cap2.86B Forward P/E- EPS next Y-3.05 Insider Trans-22.85% Shs Float19.86M Perf Month0.75%
Income-86.90M PEG- EPS next Q-0.79 Inst Own62.30% Short Float13.30% Perf Quarter68.04%
Sales- P/S- EPS this Y-35.60% Inst Trans-0.81% Short Ratio9.56 Perf Half Y178.47%
Book/sh4.80 P/B19.51 EPS next Y1.00% ROA-47.60% Target Price97.71 Perf Year94.33%
Cash/sh4.25 P/C22.03 EPS next 5Y18.30% ROE-52.80% 52W Range26.66 - 121.98 Perf YTD237.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.23% Beta-
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low251.26% ATR6.65
Employees37 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)55.94 Volatility5.93% 7.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.90% Profit Margin- Rel Volume0.74 Prev Close92.15
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume276.33K Price93.65
Recom2.70 SMA201.83% SMA5013.74% SMA20087.52% Volume203,639 Change1.63%
Apr-26-21Resumed Credit Suisse Underperform $14
Feb-17-21Downgrade Jefferies Buy → Hold $59 → $34
Dec-11-20Initiated Citigroup Sell $20
Jun-24-20Initiated H.C. Wainwright Buy $76
Jun-02-20Initiated Jefferies Buy $59
Jun-03-19Initiated JMP Securities Mkt Outperform $53
Jun-03-19Initiated Credit Suisse Underperform $14
Jun-03-19Initiated Canaccord Genuity Buy $42
Jun-03-19Initiated BofA/Merrill Neutral $28
Sep-08-21 08:00AM  
Sep-07-21 08:00AM  
Aug-25-21 08:00AM  
Aug-18-21 08:00AM  
Aug-09-21 08:00AM  
Aug-07-21 05:29AM  
Aug-04-21 08:00AM  
Jul-26-21 09:05AM  
Jul-23-21 08:00AM  
Jul-22-21 08:00AM  
Jul-21-21 08:00AM  
Jul-19-21 08:00AM  
Jul-08-21 08:00AM  
Jun-13-21 02:20PM  
Jun-01-21 08:00AM  
May-26-21 08:00AM  
May-10-21 08:00AM  
May-09-21 04:13AM  
May-04-21 08:00AM  
Mar-25-21 08:00AM  
Mar-21-21 09:52PM  
Mar-18-21 08:01PM  
Mar-16-21 10:00PM  
Mar-12-21 06:15AM  
Mar-10-21 08:00AM  
Mar-09-21 10:45PM  
Mar-08-21 08:00AM  
Mar-07-21 05:53PM  
Mar-03-21 03:00AM  
Feb-22-21 01:10PM  
Feb-20-21 07:00PM  
Feb-18-21 09:47PM  
Feb-17-21 11:38AM  
Feb-16-21 08:52AM  
Feb-15-21 09:13PM  
Feb-10-21 04:06PM  
Feb-08-21 08:22AM  
Feb-02-21 07:32PM  
Jan-26-21 08:00AM  
Jan-06-21 08:49AM  
Dec-07-20 12:49AM  
Dec-04-20 07:43AM  
Dec-01-20 08:40AM  
Nov-27-20 10:27AM  
Nov-20-20 10:45AM  
Nov-12-20 04:30PM  
Nov-10-20 07:12AM  
Nov-05-20 08:00AM  
Oct-19-20 08:00AM  
Sep-24-20 08:00AM  
Sep-09-20 08:00AM  
Aug-27-20 08:00AM  
Aug-18-20 09:21AM  
Aug-17-20 08:00AM  
Aug-14-20 08:00AM  
Aug-12-20 08:11AM  
Aug-06-20 04:05PM  
Jul-29-20 08:00AM  
Jul-28-20 06:09PM  
Jul-22-20 08:00AM  
Jun-14-20 07:00AM  
Jun-12-20 04:27PM  
Jun-09-20 08:00AM  
Jun-02-20 09:44AM  
May-27-20 08:00AM  
May-14-20 11:44AM  
May-12-20 04:05PM  
May-07-20 08:00AM  
May-06-20 08:30AM  
Apr-30-20 04:05PM  
Apr-06-20 08:30AM  
Apr-02-20 08:00AM  
Mar-17-20 08:00AM  
Mar-16-20 08:00AM  
Feb-13-20 08:00AM  
Feb-10-20 04:05PM  
Feb-05-20 09:00PM  
Jan-30-20 08:18AM  
Jan-13-20 08:00AM  
Jan-08-20 04:05PM  
Jan-05-20 08:14AM  
Jan-03-20 10:15AM  
Dec-22-19 06:38PM  
Dec-13-19 11:16AM  
Dec-11-19 06:32PM  
Dec-09-19 08:44AM  
Dec-07-19 01:00PM  
Dec-02-19 01:56PM  
Nov-26-19 04:05PM  
Nov-12-19 04:05PM  
Nov-08-19 10:34AM  
Nov-07-19 08:18AM  
Nov-01-19 08:00AM  
Oct-09-19 09:14AM  
Oct-07-19 09:36AM  
Sep-26-19 08:00AM  
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LOWE CHRISTOPHER P.COO & Chief Financial OfficerAug 17Option Exercise2.2330,00066,90060,000Aug 18 05:25 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerAug 16Option Exercise2.2322,00049,06052,000Aug 18 05:25 PM
McLoughlin MargaretDirectorAug 16Option Exercise17.006,000102,0006,000Aug 18 05:30 PM
LOWE CHRISTOPHER P.COO & Chief Financial OfficerAug 16Sale95.3122,0002,096,77930,000Aug 18 05:25 PM
McLoughlin MargaretDirectorAug 16Sale95.446,000572,6440Aug 18 05:30 PM
Detke Michael J.Chief Medical OfficerAug 10Option Exercise2.2310,00022,30010,000Aug 12 05:37 PM
Detke Michael J.Chief Medical OfficerAug 10Sale100.0010,0001,000,0000Aug 12 05:37 PM
Detke Michael J.Chief Medical OfficerJul 07Option Exercise2.2317,40038,80217,400Jul 07 08:38 PM
Detke Michael J.Chief Medical OfficerJul 07Sale55.2017,400960,5490Jul 07 08:38 PM
Detke Michael J.Chief Medical OfficerJul 06Option Exercise2.2312,60028,09840,861Jul 07 08:38 PM
Detke Michael J.Chief Medical OfficerJul 06Sale53.5440,8612,187,6230Jul 07 08:38 PM
McLoughlin MargaretDirectorJun 28Sale55.1555030,3320Jun 29 05:26 PM
Lynch CaseyChief Executive OfficerMay 10Sale34.5830,0001,037,361978,774May 12 04:51 PM
Lamond DavidDirectorMar 24Buy33.7750,0001,688,5001,847,109Mar 24 09:06 PM
Lynch CaseyChief Executive OfficerMar 22Sale35.5930,0001,067,6111,008,774Mar 23 07:06 PM
Lamond DavidDirectorMar 04Buy35.3450,0001,767,0571,797,109Mar 05 05:54 PM
Lynch CaseyChief Executive OfficerFeb 03Sale43.0320,000860,5301,038,774Feb 03 07:45 PM
Lynch CaseyChief Executive OfficerFeb 02Sale36.2120,000724,1021,058,774Feb 03 07:45 PM
Lynch CaseyChief Executive OfficerFeb 01Sale36.2520,000724,9681,078,774Feb 03 07:45 PM
Holsinger LeslieExecutive Vice PresidentDec 14Option Exercise0.2740,00010,80043,500Dec 15 07:17 PM
Holsinger LeslieExecutive Vice PresidentDec 14Sale30.8140,0001,232,5281,800Dec 15 07:17 PM
Holsinger LeslieExecutive Vice PresidentDec 10Option Exercise0.273,5009453,500Dec 14 05:16 PM